Moderna, Inc. (LON:0A45)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 20.20B +154.9% |
| Revenue (ttm) | 1.69B -30.0% |
| Net Income | -2.42B |
| EPS | -6.18 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 112,493 |
| Open | 59.35 |
| Previous Close | 59.05 |
| Day's Range | 58.55 - 69.31 |
| 52-Week Range | 22.25 - 69.31 |
| Beta | 1.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provid... [Read more]
Financial Performance
In 2025, Moderna's revenue was $1.94 billion, a decrease of -39.93% compared to the previous year's $3.24 billion. Losses were -$2.82 billion, -20.75% less than in 2024.
Financial numbers in USD Financial StatementsNews
Moderna stock soars as cancer pipeline and CAR-T push ignite optimism
Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains ...
Why Moderna (MRNA) Stock Is Soaring Today – June 26, 2026
Moderna ($MRNA) stock jumped nearly 15% at one point on Friday to around $69 per share after investors reacted positively to the biotech firm’s latest Science Day update. The move…
Why Moderna Stock Is Soaring and Leading the S&P 500 Today
Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.
Moderna price target raised to $77 from $69 at Piper Sandler
Piper Sandler raised the firm’s price target on Moderna (MRNA) to $77 from $69 and keeps an Overweight rating on the shares.
Moderna Transcript: Science Day 2026
The event outlined a multi-horizon strategy leveraging AI, automation, and multiplexing to accelerate mRNA-based innovation across infectious disease, oncology, autoimmune, and rare diseases. Key pipeline updates include promising clinical and preclinical data in cancer, MS, and autoimmune programs, with financial guidance and commercialization strategies supporting continued growth.
Moderna Slides: FY 2026
Moderna has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 25, 2026.
Moderna Science Day highlights potential of mRNA platform
Moderna (MRNA) announced research and early development updates at its Science Day event. Moderna is executing a strategy that balances near-term growth with long-term innovation. Building on the mome...
Moderna Science Day Highlights Expanding Potential of mRNA Platform
Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights validation of T-cell engager modality with mRNA-2808 in multiple myel...
FDA Votes in Favor of Benefit-Risk Profile for Moderna's Flu Vaccine
Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 5...
Moderna announces FDA advisory committee votes in favor of mRNA-1010
Moderna (MRNA) announced that the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 9-0 that the benefits of mRNA-1010, Moderna’s investigational se...
Moderna up 4% after FDA advisers back flu vaccine approval
Shares of Moderna (MRNA) are up $2.48, or 4%, to $64.28 in afternoon trading after members of the FDA’s Vaccines and Related Biological Products Advisory Committee voted 9-0 in favor…
Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of the Benefit-Risk Profile of mRNA-1010, an Investigational Seasonal Influenza Vaccine
FDA Prescription Drug User Fee Act (PDUFA) goal date remains August 5, 2026 CAMBRIDGE, MA / ACCESS Newswire / June 18, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Ad...
Jefferies’ confidence in Moderna’s mRNA flu shot rises after AdCom support
Jefferies reiterated a Hold rating and $45 price target on Moderna (MRNA) after the FDA’s Advisory Committee voted 9-0 in favor of a full approval for Moderna’s mFLUSIVA mRNA seasonal…
US FDA advisers vote in favor of Moderna's flu vaccine
The U.S. Food and Drug Administration's advisers on Thursday backed approval of Moderna's flu vaccine in adults aged 50 and older, saying its benefits outweigh the risks.
FDA panel backs Moderna mRNA-based influenza vaccine, Bloomberg reports
FDA advisers note benefits of Moderna’s (MRNA) flu vaccine outweigh the risks in adults aged between 50 and 64 and said the benefits outweigh the risks in adults aged 65…
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny
The U.S. Food and Drug Administration's advisory panel is set to vote on whether the benefits of Moderna's flu vaccine outweigh its risks in older adults, after regulators reversed course on rejectin...
Moderna to Host Investor Event - Science Day
CAMBRIDGE, MA / ACCESS Newswire / June 17, 2026 / Moderna, Inc. (Nasdaq:MRNA) today announced that it will host its Investor Event - Science Day at 9:00am ET on Thursday, June 25, 2026. The event will...
Moderna interested in Germany production, sees opportunity in BioNTech closures, says CEO
U.S. pharmaceutical company Moderna is interested in investing in production facilities in Germany, with an eye on plants that its German rival BioNTech plans to close, CEO Stephane Bancel tol...
BofA says VRBPAC docs look supportive but keeps Moderna at Underperform
BofA reviewed the VRBPAC briefing docs released this morning. Overall, the tone of the documents and proposed points of focus should foster some debate but look supportive for approval, the…
FDA posts briefing docs for meeting to discuss Moderna influenza vaccine
On June 18, the FDA is convening a meeting of the Vaccines and Related Biological Products Advisory Committee to discuss the benefit-risk assessment of mFlusiva, an mRNA-based trivalent influenza vacc...
Moderna flu vaccine briefing docs ‘read favorably,’ says Jefferies
Ahead of the FDA hosting an advisory committee meeting on Moderna’s (MRNA) mFLUSIVA mRNA vaccine for seasonal flu on Thursday, Jefferies says the firm finds the FDA’s tone and analyses…
US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults
The U.S. Food and Drug Administration's staff reviewers said preliminary assessment of Moderna's flu shot data may support effectiveness in adults 65 years and older.